title: Methylphenidate and nortriptyline in the treatment of poststroke depression: a retrospective comparison.
abstract: The hospital charts of elderly stroke patients with major depression, as determined by DSM-III-R criteria, who were treated with either methylphenidate (n = 28) or nortriptyline (n = 30) were retrospectively reviewed. Fifty-three percent of the methylphenidate patients experienced complete remission of depressive symptoms. Similarly, 43% of the patients in the nortriptyline group showed remission of depressive symptomatology. Whereas the response rates between the two treatment groups were not significantly different in the patients who did respond to treatment (chi 2 = .608, df = 1, p = NS), the speed of response was significantly better in the methylphenidate group (t[13] = 15.9, p < .001). The average peak response time for the methylphenidate patients was 2.4 days compared to 27 days for the nortriptyline group. This finding is consistent with previous reports suggesting a rapid response to methylphenidate and other psychostimulants, typically between 24 and 72 hours. Adverse side effects, such as cardiac changes, did not differ between groups, generally falling in the mild range of severity. These data suggest that the rapid effects of methylphenidate may be especially useful to speed recovery from depression so that patients can participate more fully in rehabilitation programs.
authors.affiliation: Department of Psychiatry, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612.
authors.forename: L W
authors.initials: LW
authors.lastname: Lazarus
authors.forename: P J
authors.initials: PJ
authors.lastname: Moberg
authors.forename: P R
authors.initials: PR
authors.lastname: Langsley
authors.forename: V R
authors.initials: VR
authors.lastname: Lingam
mesh_terms: D000368:Aged; D002561:Cerebrovascular Disorders / Q000150:complications* / Q000523:psychology*; D003866:Depressive Disorder / Q000145:classification / Q000188:drug therapy* / Q000209:etiology*; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000097:blood / Q000627:therapeutic use*; D009661:Nortriptyline / Q000097:blood / Q000627:therapeutic use*; D012074:Remission Induction; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D008774:Methylphenidate; D009661:Nortriptyline